日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

抗 GM-CSF 奥替利单抗治疗类风湿性关节炎患者的长期安全性和有效性：三项 3 期随机试验的长期扩展研究 (contRAst X)

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-088869
Weinblatt, Michael E; Taylor, Peter C; McInnes, Iain B; Atsumi, Tatsuya; Strand, Vibeke; Takeuchi, Tsutomu; Bracher, Marguerite; Brooks, David; Curtis, Paula; Gupta, Anubha; Nijhawan, Rina; O'Shea, Ciara; Rayner, Kirsty; Saurigny, Didier; Shelton, Celia; Wang, Millie; Wang, Reena; Fleischmann, Roy M
关节炎
GM-CSF
M-CSF
发表日期：2025
文献求助 收藏

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

抗 GM-CSF 奥替利单抗与沙利鲁单抗或安慰剂治疗对靶向治疗反应不足的类风湿性关节炎患者：一项 III 期随机试验 (contTRAst 3)

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2023-224449
Taylor, Peter C; Weinblatt, Michael E; McInnes, Iain B; Atsumi, Tatsuya; Strand, Vibeke; Takeuchi, Tsutomu; Bracher, Marguerite; Brooks, David; Davies, John; Goode, Christopher; Gupta, Anubha; Mukherjee, Sumanta; O'Shea, Ciara; Saurigny, Didier; Schifano, Lorrie A; Shelton, Celia; Smith, Julia E; Wang, Millie; Wang, Reena; Watts, Sarah; Fleischmann, Roy M
关节炎
GM-CSF
M-CSF
发表日期：2023
文献求助 收藏

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

抗 GM-CSF 奥替利单抗与托法替尼或安慰剂在活动性类风湿关节炎且对传统或生物 DMARD 反应不足的患者中的疗效比较：两项 3 期随机试验（contTRAst 1 和 contTRAst 2）

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2023-224482
Fleischmann, Roy M; van der Heijde, Désirée; Strand, Vibeke; Atsumi, Tatsuya; McInnes, Iain B; Takeuchi, Tsutomu; Taylor, Peter C; Bracher, Marguerite; Brooks, David; Davies, John; Goode, Christopher; Gupta, Anubha; Mukherjee, Sumanta; O'Shea, Ciara; Saurigny, Didier; Schifano, Lorrie A; Shelton, Celia; Smith, Julia E; Wang, Millie; Wang, Reena; Watts, Sarah; Weinblatt, Michael E
关节炎
GM-CSF
M-CSF
发表日期：2023
文献求助 收藏

Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

一项随机对照试验评估了纳米单抗（一种针对粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 配体的人源单克隆抗体）治疗对甲氨蝶呤背景治疗反应不足或对TNF（肿瘤坏死因子）生物制剂治疗反应不足或不耐受的类风湿性关节炎 (RA) 患者的疗效和安全性。

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-019-1879-x
Taylor, Peter C; Saurigny, Didier; Vencovsky, Jiri; Takeuchi, Tsutomu; Nakamura, Tadashi; Matsievskaia, Galina; Hunt, Barbara; Wagner, Thomas; Souberbielle, Bernard
单克隆抗体
巨噬细胞
肿瘤
肿瘤免疫
细胞生物学
巨噬细胞
粒细胞
M-CSF
关节炎
GM-CSF
免疫/内分泌
发表日期：2019
文献求助 收藏

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

一项针对轻度至中度类风湿性关节炎患者的namilumab（一种抗粒细胞巨噬细胞集落刺激因子单克隆抗体）的1b期随机、双盲研究

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-017-1267-3
Huizinga, T W J; Batalov, A; Stoilov, R; Lloyd, E; Wagner, T; Saurigny, D; Souberbielle, B; Esfandiari, E
单克隆抗体
巨噬细胞
细胞生物学
巨噬细胞
粒细胞
关节炎
免疫/内分泌
发表日期：2017
文献求助 收藏